Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | RHOC | P08134 | 1/20 | 0.40 |
| ▸ | RHOA | P61586 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PHGDH | O43175 | 6/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12128231 | 0.78 | SMN1; SMN2 (0.38) | LMNAGAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12130565 | 0.75 | PTGS2 (0.46) | LMNAKMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL12130337 | 0.75 | TRPA1 (0.45) | RHOCRHOAGAAKMT2AHTT | |
| SCHEMBL16904557 | 0.74 | CTSC (0.43) | LMNAGAAKMT2AHTTMEN1 | |
| SCHEMBL1968459 | 0.74 | MALT1 (0.46) | LMNARHOCRHOAKMT2AMEN1 | |
| SCHEMBL627496 | 0.74 | GAA (0.56) | LMNAGAAKMT2ANPSR1MAPT | |
| SCHEMBL16904560 | 0.72 | MALT1 (0.42) | LMNARHOCRHOAPAK1 | |
| SCHEMBL12130294 | 0.71 | TYK2 (0.44) | LMNARHOA | |
| SCHEMBL24512914 | 0.68 | RHOC (0.44) | RHOCRHOAKMT2AMEN1MAPT | |
| SCHEMBL24632339 | 0.68 | RHOC (0.44) | RHOCRHOAKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550757-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-2542089-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2014-06-05 | — | — | US | disclosed |
| US-8513230-B2 | Nuclear transport modulators and uses thereof | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2011109799-A1 | NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | LMNA 158/4885RHOC 3167/4885RHOA 2445/4885 |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | LMNA 158/4885RHOC 3167/4885RHOA 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.